Literature DB >> 18998141

Patients with active rheumatoid arthritis but only few tender and swollen joints: a subgroup with impaired short term outcome.

C Fiehn1, S Kessler, W Drexler, H M Lorenz.   

Abstract

The disease activity score of 28 joints (DAS28) is now commonly used for the guidance of treatment decisions in rheumatoid arthritis (RA). The goal of this work was to determine whether patients with DAS28 > 3.2 but less than 2 swollen and 2 tender joints respond differently to treatment than patients with a higher number of active joints. One hundred and ninety two patients with active RA treated in a rheumatology hospital as in-patients were studied prospectively. At admission (T1), release (T2) and 3 months after release (T3) disease activity (DAS28-CRP at T1 + 2, RADAI at T1 + 3), pain (numeric scale at T1 - 3) and function (FFbH at T1 + 3) were measured. A total of 148 patients had two or more (group 1) and 44 less than 2 swollen and tender joints at admission (group 2) but both groups had similar over all DAS28-scores. The groups significantly differed in their outcome after 3 months: group 1 had a significant better reduction of disease activity, pain and functional deficit (p < 0.001 for the fulfilment of defined response criteria and p < 0.05 for comparison of the mean values for pain and function) in comparison to group 2. Although the numbers were small sub-analysis suggested that the differences might be due to a better response to newly administered DMARD and TNF-alpha-inhibitor therapy in group 1. Active RA patients with less than 2 swollen and 2 tender joints represent a subgroup with lower response to treatment with DMARD or TNF-alpha-inhibitors. This has to be taken into account in the management of these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18998141     DOI: 10.1007/s00296-008-0753-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  16 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Authors:  Lars Klareskog; Désirée van der Heijde; Julien P de Jager; Andrew Gough; Joachim Kalden; Michel Malaise; Emilio Martín Mola; Karel Pavelka; Jacques Sany; Lucas Settas; Joseph Wajdula; Ronald Pedersen; Saeed Fatenejad; Marie Sanda
Journal:  Lancet       Date:  2004-02-28       Impact factor: 79.321

3.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

Authors:  Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans
Journal:  Arthritis Rheum       Date:  2005-11

4.  Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission.

Authors:  R Landewé; D van der Heijde; S van der Linden; M Boers
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

5.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

6.  Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values.

Authors:  Eisuke Inoue; Hisashi Yamanaka; Masako Hara; Taisuke Tomatsu; Naoyuki Kamatani
Journal:  Ann Rheum Dis       Date:  2006-08-22       Impact factor: 19.103

7.  Responsiveness of the self-assessed rheumatoid arthritis disease activity index to a flare of disease activity.

Authors:  J Fransen; H Häuselmann; B A Michel; M Caravatti; G Stucki
Journal:  Arthritis Rheum       Date:  2001-01

8.  Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.

Authors:  Angela Zink; Anja Strangfeld; Matthias Schneider; Peter Herzer; Franka Hierse; Maria Stoyanova-Scholz; Siegfried Wassenberg; Andreas Kapelle; Joachim Listing
Journal:  Arthritis Rheum       Date:  2006-11

9.  Disease activity score-28 values differ considerably depending on patient's pain perception and sex.

Authors:  Burkhard F Leeb; Pia M Haindl; Adil Maktari; Thomas Nothnagl; Bernhard Rintelen
Journal:  J Rheumatol       Date:  2007-11-01       Impact factor: 4.666

10.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.